Related Experiment Video
Updated: Jun 23, 2026
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Alpha-helix targeting reduces amyloid-beta peptide toxicity.
C Nerelius1, A Sandegren, H Sargsyan
1Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, The Biomedical Centre, Uppsala, Sweden.
Summary
Researchers developed novel compounds that stabilize a specific region of amyloid-beta (Abeta) peptides. This approach reduces Abeta toxicity and neurodegeneration, offering a new strategy for Alzheimer's disease treatment.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Amyloid-beta (Abeta) peptide oligomers are implicated in Alzheimer's disease neuropathology.
- Existing Abeta polymerization inhibitors have limitations, including nonspecific aggregation and potential for increased toxicity.
Purpose of the Study:
- To develop a novel therapeutic strategy targeting the Abeta peptide.
- To design specific inhibitors that stabilize a key Abeta conformation, counteracting toxic oligomer formation.
Main Methods:
- Designed ligands to bind and stabilize the 13-26 region of Abeta in an alpha-helical conformation.
- Tested compound efficacy in cell cultures, hippocampal slice preparations, and Drosophila melanogaster models.
- Assessed Abeta toxicity, aggregation properties, lifespan, locomotor activity, and neurodegeneration.
Main Results:
- Two distinct compound classes successfully stabilized the Abeta alpha-helix.
- Compounds reduced Abeta toxicity in vitro and in ex vivo preparations without nonspecific aggregation.
- In vivo studies showed prolonged lifespan, improved locomotor activity, and reduced neurodegeneration in Drosophila.
Conclusions:
- Stabilizing the central Abeta alpha-helix is a viable strategy to inhibit toxic polymerization.
- This approach offers a promising therapeutic avenue for Alzheimer's disease, distinct from current inhibitor methods.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...